胰高血糖素样肽-1改善非酒精性脂肪性肝病作用机制研究进展*

doi:10.3969/j.issn.1672-5069.2018.02.047

Abstract

Xin Fengzhi, Cao Haixia, Fan Jiangao. Glucagon-like peptide-1 in melioration of non-alcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 313-316.

[1] Holst JJ.The physiology of glucagon-like peptide 1.Physiol Rev,2007,87(4):1409-1439.
[2] Lind M,Hirsch IB,Tuomilehto J,et al.Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections:randomised clinical trial(MDI Liraglutide trial). BMJ,2015,351:5364.
[3] Marso SP,Daniels GH,Brown-Frandsen K,et al.Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med,2016,375(4):311-322.
[4] Wong VW,Wong GL.A LEAN treatment for non-alcoholic steatohepatitis. Lancet,2016,387(10019):628-630.
[5] EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol,2016,64(6):1388-1402.
[6] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南.实用肝脏病杂志,2007,10(1):1-3.
[7] Dutour A,Abdesselam I,Ancel P,et al.Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes:a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab, 2016,18(9):882-891.
[8] Gupta NA,Mells J,Dunham RM,et al.Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.Hepatology,2010,51(5):1584-1592.[9] Den Besten G,Gerding A,van Dijk TH,et al. Protection against the metabolic syndrome by guar gum-derived short-chain fatty acids depends on peroxisome proliferator-activated receptor gamma and glucagon-like peptide-1. PLoS One,2015,10(8):e0136364.
[10] Armstrong MJ,Hull D,Guo K,et al.Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol,2016,64(2):399-408.
[11] Ding X,Saxena NK,Lin S,et al.Exendin-4,a glucagon-like protein-1(GLP-1) receptor agonist,reverses hepatic steatosis in ob/ob mice. Hepatology,2006,43(1):173-181.
[12] Mells JE,Fu PP,Sharma S,et al.Glp-1 analog,liraglutide,ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol,2012,302(2):225-235.
[13] Gao H,Zeng Z,Zhang H,et al.The glucagon-like peptide-1 analogue liraglutide inhibits oxidative stress and inflammatory response in the liver of rats with diet-induced non-alcoholic fatty liver disease. Biol Pharm Bull,2015,38(5):694-702.
[14] Armstrong MJ,Gaunt P,Aithal GP,et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN):a multicentre,double-blind,randomised,placebo-controlled phase 2 study. Lancet,2016,387(10019):679-690.
[15] Garcia-Compean D,Gonzalez-Gonzalez JA,Lavalle-Gonzalez FJ,et al.The treatment of diabetes mellitus of patients with chronic liver disease. Ann Hepatol,2015,14(6):780-788.
[16] Junker AE,Gluud LL,Holst JJ,et al.Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis. J Gastroenterol Hepatol,2015,30(10):1522-1528.
[17] Kahal H,Abouda G,Rigby AS,et al.Glucagon-like peptide-1 analogue,liraglutide,improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf),2014,81(4):523-528.
[18] Sanders FW,Griffin JL.De novo lipogenesis in the liver in health and disease:more than just a shunting yard for glucose.Biol Rev Camb Philos Soc,2016,91(2):452-468.
[19] Wang PX,Zhang XJ,Luo P,et al.Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling.Nat Commun,2016,7:10592.
[20] Hirata Y,Kurobe H,Nishio C,et al.Exendin-4,a glucagon-like peptide-1 receptor agonist,attenuates neointimal hyperp-lasia after vascular injury. Eur J Pharmacol,2013,699(1-3):106-111.
[21] Solmaz V,Cinar BP,Yigitturk G,et al.Exenatide reduces TNF-alpha expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. Eur J Pharmacol,2015,765:482-487.
[22] Zhang L,Yang M,Ren H,et al.GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int,2013,33(5):794-804.
[23] Chen H,Simar D,Pegg K,et al.Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents.Diabetologia,2014,57(3):614-622.
[24] Cengiz M,Yasar DG,Ergun MA,et al.The role of interleukin-6 and interleukin-8 gene polymorphisms in non-alcoholic steatohepatitis. Hepat Mon, 2014,14(12):24635.
[25] He Q,Li F,Li J,et al.MicroRNA-26a-interleukin(IL)-6-IL-17 axis regulates the development of non-alcoholic fatty liver disease in a murine model. Clin Exp Immunol,2017,187(1):174-184.
[26] Kugelmas M,Hill DB,Vivian B,et al.Cytokines and NASH:a pilot study of the effects of lifestyle modification and vitamin E.Hepatology,2003,38(2):413-419.
[27] Singh R,Kaushik S,Wang Y,et al.Autophagy regulates lipid metabolism. Nature,2009,458(7242):1131-1135.
[28] Jing Yin J,Bo Li Y,Ming Cao M,et al.Liraglutide improves the survival of INS-1 cells by promoting macroautophagy. Int J Endocrinol Metab,2013,11(3):184-190.
[29] Abe H,Uchida T,Hara A,et al.Exendin-4 improves beta-cell function in autophagy-deficient beta-cells. Endocrinology,2013,154(12):4512-4524.
[30] Zhou SW,Zhang M,Zhu M.Liraglutide reduces lipid accumulation in steatotic L02 cells by enhancing autophagy. Mol Med Rep,2014,10(5):2351-2357.
[31] Xu F,Li Z,Zheng X,et al.SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes,2014,63(11):3637-3646.
[32] Ben-Shlomo S,Zvibel I,Shnell M,et al.Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.J Hepatol,2011,54(6):1214-1223.
[33] He Q,Sha S,Sun L,et al.GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. Biochem Biophys Res Commun,2016,476(4):196-203.
[34] Czaja MJ.JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab,2010,21(12):707-713.

Glucagon-like peptide-1 in melioration of non-alcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[3]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[4]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[5]	Fu Liang, Wu Dongbing, Ji Xinzun. Application of ARFI quantification in the evaluation of liver injuries in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 377-380.
[6]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[7]	Su Shuting, Zhong Yan, Mi Yuqiang.. Management of patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 293-296.
[8]	Zhang Feng, Yan Yan.. Implication of serum apolipoprotein B levels and its correlation with metabolic syndrome in checked-up individuals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 61-64.
[9]	Song Na, Liu Xiaoyan, Liu Chang, et al.. Changes of plasma thyrotropin levels in patients with nonalcoholic fatty liver disease and type 2 diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 65-68.
[10]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[11]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[12]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[13]	Cui Ruibing, Yan Ming.. Etiology of ascites:what’s going on [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 657-660.
[14]	Li Yue, Ding Huiguo.. Current diagnosis and treatment of chylous ascites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 665-668.
[15]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.